ATE493433T1 - Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen - Google Patents
Neue zusammensetzung und verfahren zur behandlung von immunerkrankungenInfo
- Publication number
- ATE493433T1 ATE493433T1 AT03752132T AT03752132T ATE493433T1 AT E493433 T1 ATE493433 T1 AT E493433T1 AT 03752132 T AT03752132 T AT 03752132T AT 03752132 T AT03752132 T AT 03752132T AT E493433 T1 ATE493433 T1 AT E493433T1
- Authority
- AT
- Austria
- Prior art keywords
- immune diseases
- new composition
- treating immune
- treating
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41006202P | 2002-09-11 | 2002-09-11 | |
| PCT/US2003/028202 WO2004024068A2 (en) | 2002-09-11 | 2003-09-09 | Novel composition and methods for the treatment of immune related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE493433T1 true ATE493433T1 (de) | 2011-01-15 |
Family
ID=31994051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03752132T ATE493433T1 (de) | 2002-09-11 | 2003-09-09 | Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen |
Country Status (9)
| Country | Link |
|---|---|
| US (6) | US20040121370A1 (de) |
| EP (3) | EP2277532A1 (de) |
| JP (2) | JP5401001B2 (de) |
| AT (1) | ATE493433T1 (de) |
| AU (2) | AU2003270439B2 (de) |
| CA (1) | CA2498008C (de) |
| DE (1) | DE60335552D1 (de) |
| ES (1) | ES2357505T3 (de) |
| WO (1) | WO2004024068A2 (de) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE493433T1 (de) | 2002-09-11 | 2011-01-15 | Genentech Inc | Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen |
| EP2399932B1 (de) | 2005-05-12 | 2016-11-16 | ZymoGenetics, Inc. | Zusammensetzungen und Verfahren zur Modulation von Immunantworten |
| EP2004682A2 (de) * | 2006-04-13 | 2008-12-24 | Zymogenetics, Inc. | Tetramerisierende polypeptide und verwendungsverfahren dafür |
| US20100075377A1 (en) * | 2006-04-13 | 2010-03-25 | West James W | Tetramerizing polypeptides and methods of use |
| AU2015202123B2 (en) * | 2008-04-09 | 2017-06-15 | Genentech, Inc. | Novel compositions and methods for the treatment of immune related diseases |
| KR101924831B1 (ko) * | 2008-04-09 | 2018-12-05 | 제넨테크, 인크. | 면역 관련 질병의 치료를 위한 신규한 조성물 및 방법 |
| EA029958B1 (ru) | 2011-09-23 | 2018-06-29 | Онкомед Фармасьютикалс, Инк. | Антитела, связывающие фактор роста эндотелия сосудов (vegf)/дельта-подобный лиганд (dll4), и их применение |
| PL3021869T3 (pl) | 2013-07-16 | 2020-11-16 | F. Hoffmann-La Roche Ag | Sposoby leczenia nowotworu z użyciem antagonistów wiązania osi PD-1 i inhibitorów TIGIT |
| GEP20217331B (en) | 2014-08-19 | 2021-12-10 | Merck Sharp & Dohme Corp Us | Anti-tigit antibodies |
| KR102644115B1 (ko) | 2014-12-23 | 2024-03-05 | 브리스톨-마이어스 스큅 컴퍼니 | Tigit에 대한 항체 |
| MA41460A (fr) | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
| WO2016134333A1 (en) | 2015-02-19 | 2016-08-25 | Compugen Ltd. | Anti-pvrig antibodies and methods of use |
| WO2016134335A2 (en) | 2015-02-19 | 2016-08-25 | Compugen Ltd. | Pvrig polypeptides and methods of treatment |
| TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| CN108290936B (zh) | 2015-08-14 | 2022-07-12 | 默沙东公司 | 抗tigit抗体 |
| US10946095B2 (en) | 2015-09-02 | 2021-03-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT) |
| AU2016326609B2 (en) | 2015-09-23 | 2023-03-09 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
| CR20220186A (es) | 2015-09-25 | 2022-07-07 | Genentech Inc | ANTICUERPOS ANTI-TIGIT Y MÉTODOS DE USO (divisional 2018-0225) |
| BR112018006531A2 (pt) | 2015-10-01 | 2018-12-11 | Potenza Therapeutics Inc | proteína isolada de ligação ao antígeno (abp), polinucleotídeo isolado, vetor, célula hospedeira, método para produzir uma proteína isolada de ligação ao antígeno (abp), composição farmacêutica, método para tratar ou prevenir uma doença ou condição num sujeito em necessidade deste, método para modular uma resposta imune num indivíduo em necessidade deste e kit |
| EP3423089A4 (de) | 2016-03-04 | 2019-10-23 | JN Biosciences, LLC | Anti-tigit-antikörper |
| EP3347379B9 (de) | 2016-08-17 | 2020-03-25 | Compugen Ltd. | Anti-tigit-antikörper, anti-pvrig-antikörper und kombinationen daraus |
| JP7126269B2 (ja) | 2016-11-30 | 2022-08-26 | メレオ バイオファーマ ５ インコーポレイテッド | Ｔｉｇｉｔ結合物質を含む、がんの処置のための方法 |
| US10759855B2 (en) | 2016-12-02 | 2020-09-01 | Rigel Pharmaceuticals, Inc. | Antigen binding molecules to TIGIT |
| JOP20190203A1 (ar) | 2017-03-30 | 2019-09-03 | Potenza Therapeutics Inc | بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها |
| MA50957A (fr) | 2017-05-01 | 2020-10-14 | Agenus Inc | Anticorps anti-tigit et leurs méthodes d'utilisation |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| CN110799213A (zh) | 2017-06-01 | 2020-02-14 | 康姆普根有限公司 | 三联组合抗体疗法 |
| US20200407445A1 (en) | 2017-07-27 | 2020-12-31 | Iteos Therapeutics Sa | Anti-tigit antibodies |
| US11401339B2 (en) | 2018-08-23 | 2022-08-02 | Seagen Inc. | Anti-TIGIT antibodies |
| AR117327A1 (es) | 2018-12-20 | 2021-07-28 | 23Andme Inc | Anticuerpos anti-cd96 y métodos de uso de estos |
| BR112022000628A2 (pt) | 2019-07-15 | 2022-03-03 | Shanghai Junshi Biosciences Co Ltd | Anticorpos anti-tigit e aplicação dos mesmos |
| JP2023528036A (ja) | 2020-06-02 | 2023-07-03 | アーカス バイオサイエンシズ インコーポレイティド | Ｔｉｇｉｔに対する抗体 |
| AU2021293507A1 (en) | 2020-06-18 | 2023-02-02 | F. Hoffmann-La Roche Ag | Treatment with anti-TIGIT antibodies and PD-1 axis binding antagonists |
| TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷 |
| WO2022044010A1 (en) | 2020-08-26 | 2022-03-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Anti-t-cell immunoglobulin and itim domain (tigit) antibodies for the treatment of fungal infections |
| AU2022207020A1 (en) | 2021-01-14 | 2023-08-31 | Shanghai Junshi Biosciences Co., Ltd. | Anti-tigit antibody pharmaceutical composition and application thereof |
| TW202304965A (zh) | 2021-05-04 | 2023-02-01 | 美商艾吉納斯公司 | 抗ｔｉｇｉｔ抗體、抗ｃｄ９６抗體及其使用方法 |
| WO2023010094A2 (en) | 2021-07-28 | 2023-02-02 | Genentech, Inc. | Methods and compositions for treating cancer |
| TW202321308A (zh) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法 |
| WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
| WO2024186790A1 (en) | 2023-03-06 | 2024-09-12 | Genentech, Inc. | Prognostic and therapeutic methods for non-small cell lung cancer |
Family Cites Families (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4943529A (en) | 1982-05-19 | 1990-07-24 | Gist-Brocades Nv | Kluyveromyces as a host strain |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| AU3145184A (en) | 1983-08-16 | 1985-02-21 | Zymogenetics Inc. | High expression of foreign genes in schizosaccharomyces pombe |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4736866A (en) | 1984-06-22 | 1988-04-12 | President And Fellows Of Harvard College | Transgenic non-human mammals |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| EP0206448B1 (de) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hämoglobin, das an ein Poly(alkenylenoxid) gebunden ist |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4946783A (en) | 1987-01-30 | 1990-08-07 | President And Fellows Of Harvard College | Periplasmic protease mutants of Escherichia coli |
| US5010182A (en) | 1987-07-28 | 1991-04-23 | Chiron Corporation | DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides |
| IL87737A (en) | 1987-09-11 | 1993-08-18 | Genentech Inc | Method for culturing polypeptide factor dependent vertebrate recombinant cells |
| GB8724885D0 (en) | 1987-10-23 | 1987-11-25 | Binns M M | Fowlpox virus promotors |
| WO1989005859A1 (en) | 1987-12-21 | 1989-06-29 | The Upjohn Company | Agrobacterium mediated transformation of germinating plant seeds |
| AU4005289A (en) | 1988-08-25 | 1990-03-01 | Smithkline Beecham Corporation | Recombinant saccharomyces |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| ES2038579T3 (es) | 1989-04-28 | 1997-02-16 | Rhein Biotech Proz & Prod Gmbh | Celulas de levadura del genero schwanniomyces. |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (de) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformationsvektoren für Hefe Yarrowia |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| CA2062795A1 (en) | 1989-06-29 | 1990-12-30 | Michael W. Fanger | Bispecific reagents for aids therapy |
| FR2649120B1 (fr) | 1989-06-30 | 1994-01-28 | Cayla | Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| DE69303494T2 (de) | 1992-11-13 | 1997-01-16 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| ES2141128T3 (es) | 1993-03-24 | 2000-03-16 | Berlex Biosciences | Combinacion de agentes anti-hormonales y moleculas de fijacion. |
| US5989811A (en) * | 1994-09-29 | 1999-11-23 | Urocor, Inc. | Sextant core biopsy predictive mechanism for non-organ confined disease status |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5750345A (en) * | 1995-10-31 | 1998-05-12 | Evanston Hospital Corporation | Detection of human α-thalassemia mutations and their use as predictors of blood-related disorders |
| WO1997033551A2 (en) | 1996-03-15 | 1997-09-18 | Millennium Pharmaceuticals | Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation |
| DK1516629T3 (da) | 1996-11-27 | 2013-06-03 | Genentech Inc | Humaniseret anti-CD-11a antibodies |
| WO1999063063A1 (en) | 1998-06-03 | 1999-12-09 | Northwestern University | Cellular proteins which mediate herpesvirus entry |
| US6518033B1 (en) | 1998-08-05 | 2003-02-11 | The Research Foundation Of State University Of New York | Method of detecting the presence of CD155 for diagnosis of cancer and to determine treatment |
| EP1220905A2 (de) * | 1999-03-08 | 2002-07-10 | Genentech Inc. | Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten |
| EP1173462A1 (de) * | 1999-03-26 | 2002-01-23 | Human Genome Sciences, Inc. | 50 menschlische sekretierte hormone |
| US7282570B2 (en) * | 1999-04-20 | 2007-10-16 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| EP1198568B1 (de) * | 1999-07-20 | 2007-07-25 | Genentech, Inc. | Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten |
| US20080050809A1 (en) * | 1999-09-28 | 2008-02-28 | Alejandro Abuin | Novel human kinases and polynucleotides encoding the same |
| WO2001029221A2 (en) | 1999-10-20 | 2001-04-26 | Zymogenetics, Inc. | Proteins and polynucleotides encoding them |
| US20040219521A1 (en) * | 2000-01-21 | 2004-11-04 | Tang Y. Tom | Novel nucleic acids and polypeptides |
| US20020081597A1 (en) | 2000-03-31 | 2002-06-27 | Genentech, Inc. | Compositions and methods for detecting and quantifying gene expression |
| US6569668B2 (en) | 2000-04-04 | 2003-05-27 | Schering Corporation | Isolated nucleic acids from Micromonospora rosaria plasmid pMR2 and vectors made therefrom |
| CA2412377A1 (en) | 2000-06-06 | 2001-12-13 | Bristol-Myers Squibb Company | B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
| US20040101876A1 (en) | 2002-05-31 | 2004-05-27 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| CA2469941A1 (en) | 2001-12-10 | 2003-07-03 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
| WO2003068943A2 (en) * | 2002-02-13 | 2003-08-21 | Incyte Corporation | Secreted proteins |
| CA2476518A1 (en) | 2002-02-22 | 2003-09-04 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
| PT2206517T (pt) | 2002-07-03 | 2023-11-07 | Tasuku Honjo | Composições de imunopotenciação contendo anticorpos anti-pd-l1 |
| US20060199181A1 (en) | 2002-09-11 | 2006-09-07 | Genentch, Inc. | Compositions and methods for the treatment of immune related diseases |
| ATE493433T1 (de) | 2002-09-11 | 2011-01-15 | Genentech Inc | Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen |
| EP1481993A1 (de) | 2003-05-28 | 2004-12-01 | Xerion Pharmaceuticals AG | Modulation der Funktion des Poliovirus-Rezeptors |
| TW200526684A (en) | 2003-11-21 | 2005-08-16 | Schering Corp | Anti-IGFR1 antibody therapeutic combinations |
| AU2004293180B2 (en) | 2003-11-28 | 2011-09-15 | Astrazeneca Ab | Antibodies binding to a C-terminal fragment of Apolipoprotein E |
| CN101035807A (zh) | 2004-06-09 | 2007-09-12 | 泰勒公司 | Siglec－6相关疾病的诊断和治疗 |
| AR052774A1 (es) | 2004-10-08 | 2007-04-04 | Wyeth Corp | Inmunoterapia para trastornos autoinmunes |
| US8008449B2 (en) | 2005-05-09 | 2011-08-30 | Medarex, Inc. | Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| EP2399932B1 (de) | 2005-05-12 | 2016-11-16 | ZymoGenetics, Inc. | Zusammensetzungen und Verfahren zur Modulation von Immunantworten |
| EP2004682A2 (de) | 2006-04-13 | 2008-12-24 | Zymogenetics, Inc. | Tetramerisierende polypeptide und verwendungsverfahren dafür |
| US20100075377A1 (en) | 2006-04-13 | 2010-03-25 | West James W | Tetramerizing polypeptides and methods of use |
| EP2007806A2 (de) | 2006-04-13 | 2008-12-31 | ZymoGenetics, Inc. | Tetramerisierende polypeptide und verwendungsverfahren dafür |
| WO2007124383A2 (en) | 2006-04-19 | 2007-11-01 | Oregon Health & Science University | 1,1'-binaphthyl-based inhibitors of nad+-dependent deacetylase activity and sir2-family members |
| KR101924831B1 (ko) | 2008-04-09 | 2018-12-05 | 제넨테크, 인크. | 면역 관련 질병의 치료를 위한 신규한 조성물 및 방법 |
| BRPI0917592B1 (pt) | 2008-12-09 | 2021-08-17 | Genentech, Inc | Anticorpo anti-pd-l1, composição, artigos manufaturados e usos de uma composição |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| WO2011156356A1 (en) | 2010-06-09 | 2011-12-15 | Zymogenetics, Inc. | Dimeric vstm3 fusion proteins and related compositions and methods |
| TWI835048B (zh) | 2011-08-01 | 2024-03-11 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
| US9828432B2 (en) | 2012-02-06 | 2017-11-28 | Providence Health & Services—Oregon | Cancer treatment and monitoring methods using OX40 agonists |
| PL2925350T3 (pl) | 2012-12-03 | 2019-07-31 | Bristol-Myers Squibb Company | Zwiększenie aktywności przeciwnowotworowej immunomodulacyjnych białek fuzyjnych fc |
| BR112015013127A2 (pt) | 2012-12-04 | 2017-09-26 | Oncomed Pharm Inc | imunoterapia com agentes de ligação |
| US20140242077A1 (en) | 2013-01-23 | 2014-08-28 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| PL3021869T3 (pl) | 2013-07-16 | 2020-11-16 | F. Hoffmann-La Roche Ag | Sposoby leczenia nowotworu z użyciem antagonistów wiązania osi PD-1 i inhibitorów TIGIT |
| US9975957B2 (en) | 2014-03-31 | 2018-05-22 | Genentech, Inc. | Anti-OX40 antibodies and methods of use |
| MA40682B1 (fr) | 2014-03-31 | 2020-01-31 | Hoffmann La Roche | Anticorps anti-ox40 et procédés d'utilisation correspondants |
| MA40437A (fr) | 2014-07-16 | 2017-05-24 | Hoffmann La Roche | Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux |
| RU2017119428A (ru) | 2014-11-06 | 2018-12-06 | Дженентек, Инк. | Комбинированная терапия, включающая применение агонистов, связывающихся с ох40, и ингибиторов tigit |
| CR20220186A (es) | 2015-09-25 | 2022-07-07 | Genentech Inc | ANTICUERPOS ANTI-TIGIT Y MÉTODOS DE USO (divisional 2018-0225) |
-
2003
- 2003-09-09 AT AT03752132T patent/ATE493433T1/de active
- 2003-09-09 EP EP10177178A patent/EP2277532A1/de not_active Withdrawn
- 2003-09-09 EP EP09004342A patent/EP2085096A3/de not_active Ceased
- 2003-09-09 JP JP2004536371A patent/JP5401001B2/ja not_active Expired - Lifetime
- 2003-09-09 EP EP03752132A patent/EP1539228B1/de not_active Expired - Lifetime
- 2003-09-09 US US10/658,482 patent/US20040121370A1/en not_active Abandoned
- 2003-09-09 ES ES03752132T patent/ES2357505T3/es not_active Expired - Lifetime
- 2003-09-09 DE DE60335552T patent/DE60335552D1/de not_active Expired - Lifetime
- 2003-09-09 AU AU2003270439A patent/AU2003270439B2/en not_active Expired
- 2003-09-09 WO PCT/US2003/028202 patent/WO2004024068A2/en active Application Filing
- 2003-09-09 CA CA2498008A patent/CA2498008C/en not_active Expired - Lifetime
-
2006
- 2006-09-29 US US11/537,270 patent/US20090181024A1/en not_active Abandoned
-
2009
- 2009-12-16 AU AU2009250980A patent/AU2009250980A1/en not_active Withdrawn
-
2010
- 2010-03-15 JP JP2010058499A patent/JP2010187677A/ja active Pending
- 2010-12-14 US US12/967,886 patent/US8431350B2/en not_active Ceased
-
2014
- 2014-03-27 US US14/228,173 patent/USRE46816E1/en not_active Expired - Lifetime
- 2014-03-27 US US14/228,172 patent/USRE46805E1/en not_active Expired - Lifetime
-
2015
- 2015-04-29 US US14/699,845 patent/USRE46534E1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP5401001B2 (ja) | 2014-01-29 |
| AU2009250980A1 (en) | 2010-01-14 |
| WO2004024068A2 (en) | 2004-03-25 |
| WO2004024068A3 (en) | 2005-02-10 |
| US20040121370A1 (en) | 2004-06-24 |
| JP2006508649A (ja) | 2006-03-16 |
| AU2003270439A1 (en) | 2004-04-30 |
| CA2498008C (en) | 2014-02-04 |
| DE60335552D1 (de) | 2011-02-10 |
| EP1539228A4 (de) | 2006-04-05 |
| CA2498008A1 (en) | 2004-03-25 |
| US8431350B2 (en) | 2013-04-30 |
| EP1539228B1 (de) | 2010-12-29 |
| EP2277532A1 (de) | 2011-01-26 |
| ES2357505T3 (es) | 2011-04-27 |
| EP2085096A2 (de) | 2009-08-05 |
| USRE46534E1 (en) | 2017-09-05 |
| EP2085096A3 (de) | 2009-08-12 |
| EP1539228A2 (de) | 2005-06-15 |
| US20090181024A1 (en) | 2009-07-16 |
| USRE46816E1 (en) | 2018-05-01 |
| US20110104170A1 (en) | 2011-05-05 |
| AU2003270439B2 (en) | 2009-09-24 |
| JP2010187677A (ja) | 2010-09-02 |
| USRE46805E1 (en) | 2018-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE493433T1 (de) | Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen | |
| ATE497778T1 (de) | Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus | |
| DE60227095D1 (de) | Zusammensetzungen und verfahren zur behandlung von abgebundenem gips | |
| ATE516042T1 (de) | Zusammensetzungen und verfahren zur behandlung und diagnose von tumoren | |
| ATE522623T1 (de) | Zusammensetzungen und verfahren zur behandlung und diagnose von lungentumoren | |
| DE602006016934D1 (de) | Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen | |
| ATE331527T1 (de) | Verfahren zur behandlung von brustdrüsenerkrankungen | |
| ATE522229T1 (de) | Anti-ngf-antikörper zur behandlung verschiedener erkrankungen | |
| DE602004030535D1 (de) | Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor-antagonisten und eines nsaid und diese enthaltende zusammensetzung | |
| WO2005016962A3 (en) | Compositions and methods for the treatment of immune related diseases | |
| DE60124080D1 (de) | Verbindungen und verfahren zur behandlung der alzheimerschen krankheit | |
| DE602006018583D1 (de) | Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten | |
| ATE521357T1 (de) | Verfahren zur behandlung von hepatitis | |
| DE60035693D1 (de) | Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten | |
| ATE428413T1 (de) | Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen | |
| DE60034871D1 (de) | Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust | |
| DE602004002394D1 (de) | (3-ä3-'(2,4-BIS-TRIFLUORMETHYL-BENZYL)-(5-ETHYL-PYRIMIDIN-2-YL)-AMINOÜ-PROPOXYü-PHENYL)-ESSIGSÄURE UND VERWANDTE VERBINDUNGEN ALS MODULATOREN VON PPARS UND VERFAHREN ZUR BEHANDLUNG VON STOFFWECHSELSTÖRUNGEN | |
| ATE515268T1 (de) | Verwendung von op-1 zur behandlung von knorpeldefekten | |
| DE60233433D1 (de) | PHARMAZEUTISCHE ZUBEREITUNG enthaltend ein Catechin, Ascorbinsäure, Prolin und Lysin ZUR BEHANDLUNG VON NEOPLASTISCHEN KRANKHEITEN | |
| DE69634438D1 (de) | Von humanem hitzeschockprotein 60 hergeleitete peptide zur behandlung von diabetis, entsprechende zusammensetzungen, verfahren und kits | |
| DE60136748D1 (de) | Verfahren und zusammensetzungen zur behandlung von augenerkrankungen | |
| DE602004028574D1 (de) | Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie | |
| ATE473277T1 (de) | Zusammensetzungen und verfahren zur prävention und behandlung von immunvermittelten entzündungskrankheiten | |
| DE602004023100D1 (de) | Verbindungen und verfahren zur behandlung von dyslipidemie | |
| DE60126211D1 (de) | Zementklinker, zementzusammensetzung, verfahren zur herstellung von zementklinker und verfahren zur behandlung von alkalihaltigen abfällen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1539228 Country of ref document: EP |